Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IBEX Technologies Inc V.IBT

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.’s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISA’s) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.


TSXV:IBT - Post by User

Post by ARIMA11on Jan 10, 2022 11:52am
126 Views
Post# 34300072

Interesting

InterestingAndreessen Horowitz raised $9 billion in new capital for its venture capital, growth, and biotech-focused funds. More than half of the new capital is sitting in a growth fund targeting mature startups. The Silicon Valley-based venture capital firm says it plans to continue to invest across the entire spectrum of startup growth stages. The new infusion of cash brings Andreessen’s total assets under management to more than $28 billion. Source: WSJ 

https://a16z.com/2022/01/07/9b-to-build-the-future/?mod=djemCIO
https://future.a16z.com/technology-saves-the-world/

Only 15 months ago — March 13, 2020 — COVID-19 became a national emergency in the United States. My assumption at the time was that COVID lockdowns could extend as long as five years, the previous speed record for modern vaccine development, with many millions of deaths — a generational cataclysm.

Take away: The five year assumptions is interesting because  even if vaccine development did not take as long, variant can potentially take us there (certainly hope not but a possibility..)
<< Previous
Bullboard Posts
Next >>